Stay updated with breaking news from Mediated Nephritis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial ...
EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting ...
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for...
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CRC--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progres...